These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 19386420)

  • 1. Selection of appropriate serological tests to measure the incidence of natural Leishmania infantum infection during DNA/MVA prime/boost canine vaccine trials.
    Carson C; Antoniou M; Christodoulou V; Messaritakis I; Quinnell RJ; Blackwell JM; Courtenay O
    Vet Parasitol; 2009 Jun; 162(3-4):207-13. PubMed ID: 19386420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological evaluation of experimentally infected dogs by LicTXNPx-ELISA and amastigote-flow cytometry.
    Silvestre R; Santarém N; Cunha J; Cardoso L; Nieto J; Carrillo E; Moreno J; Cordeiro-da-Silva A
    Vet Parasitol; 2008 Nov; 158(1-2):23-30. PubMed ID: 18848397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.
    Carson C; Antoniou M; Ruiz-Argüello MB; Alcami A; Christodoulou V; Messaritakis I; Blackwell JM; Courtenay O
    Vaccine; 2009 Feb; 27(7):1080-6. PubMed ID: 19095029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in flow cytometric serology for canine visceral leishmaniasis: diagnostic applications when distinct clinical forms, vaccination and other canine pathogens become a challenge.
    Andrade RA; Silva Araújo MS; Reis AB; Gontijo CM; Vianna LR; Mayrink W; Martins-Filho OA
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):79-86. PubMed ID: 19046772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
    Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V
    Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of enzyme-linked immunosorbent assays, an immunofluorescent-antibody test, and two rapid tests (immunochromatographic-dipstick and gel tests) for serological diagnosis of symptomatic and asymptomatic Leishmania infections in dogs.
    Mettler M; Grimm F; Capelli G; Camp H; Deplazes P
    J Clin Microbiol; 2005 Nov; 43(11):5515-9. PubMed ID: 16272479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG subclass profile of serum antibodies to Leishmania chagasi in naturally infected and vaccinated dogs.
    Oliveira TM; Mineo TW; Bason M; Day MJ; Machado RZ
    Vet Parasitol; 2009 May; 162(1-2):16-22. PubMed ID: 19345019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
    Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
    Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
    Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canine visceral leishmaniasis in urban and rural areas of Northeast Brazil.
    Queiroz PV; Monteiro GR; Macedo VP; Rocha MA; Batista LM; Queiroz JW; Jerônimo SM; Ximenes MF
    Res Vet Sci; 2009 Apr; 86(2):267-73. PubMed ID: 18804826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
    Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A
    Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroreactivity against raw insect-derived recombinant KMPII, TRYP, and LACK Leishmania infantum proteins in infected dogs.
    Todolí F; Pérez-Filgueira M; Galindo I; Gómez-Sebastián S; Escribano JM; Rodríguez-Cortés A; Alberola J
    Vet Parasitol; 2009 Oct; 164(2-4):154-61. PubMed ID: 19570612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of an optimized dog-culling program in the dynamics of canine Leishmania transmission.
    Moreira ED; Mendes de Souza VM; Sreenivasan M; Nascimento EG; Pontes de Carvalho L
    Vet Parasitol; 2004 Aug; 122(4):245-52. PubMed ID: 15262002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of three recombinant Leishmania infantum antigens in human and canine visceral leishmaniasis diagnosis.
    Fonseca AM; Faria AR; Rodrigues FT; Nagem RA; Magalhães RD; Cunha JL; Bartholomeu DC; de Andrade HM
    Acta Trop; 2014 Sep; 137():25-30. PubMed ID: 24801885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
    Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
    Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canine visceral leishmaniasis: asymptomatic infected dogs as a source of L. infantum infection.
    Moshfe A; Mohebali M; Edrissian G; Zarei Z; Akhoundi B; Kazemi B; Jamshidi S; Mahmoodi M
    Acta Trop; 2009 Nov; 112(2):101-5. PubMed ID: 19595664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.